212 related articles for article (PubMed ID: 26339164)
21. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
22. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
Du JL; Wang YL; Shi HY; Guo AT; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
[TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.
Nart D; Yaman B; Yilmaz F; Zeytunlu M; Karasu Z; Kiliç M
Liver Transpl; 2010 May; 16(5):621-30. PubMed ID: 20440771
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma in patients without cirrhosis in Italy.
Giannini EG; Marenco S; Bruzzone L; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F
Dig Liver Dis; 2013 Feb; 45(2):164-9. PubMed ID: 23047000
[TBL] [Abstract][Full Text] [Related]
25. Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study.
Clemente C; Elba S; Buongiorno G; Guerra V; D'Attoma B; Orlando A; Russo F
Liver Int; 2007 Aug; 27(6):791-7. PubMed ID: 17617122
[TBL] [Abstract][Full Text] [Related]
26. The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma.
Ma S; Yang J; Li J; Song J
Tumour Biol; 2016 Jun; 37(6):7405-12. PubMed ID: 26676639
[TBL] [Abstract][Full Text] [Related]
27. The pretreatment albumin to globulin ratio, a validated biomarker, predicts prognosis in hepatocellular carcinoma.
Zhang J; Liu X; Yang Z; Chen Y; Luo R
J BUON; 2016; 21(4):925-934. PubMed ID: 27685915
[TBL] [Abstract][Full Text] [Related]
28. [Influence of cirrhosis on long-term outcomes after liver resection in patients with a single small hepatocellular carcinoma].
Liang BY; Huang ZY; Liu YA; Hou P; Ji GB; Chen XP
Zhonghua Wai Ke Za Zhi; 2012 Oct; 50(10):865-9. PubMed ID: 23302452
[TBL] [Abstract][Full Text] [Related]
29. Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.
Hu T; Guo H; Wang W; Yu S; Han L; Jiang L; Ma J; Yang C; Guo Q; Nan K
Oncol Rep; 2013 Oct; 30(4):1707-14. PubMed ID: 23842948
[TBL] [Abstract][Full Text] [Related]
30. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis.
Kim JM; Kwon CH; Joh JW; Park JB; Lee JH; Kim SJ; Paik SW; Park CK; Yoo BC
Ann Surg Oncol; 2014 Feb; 21(2):458-65. PubMed ID: 24132624
[TBL] [Abstract][Full Text] [Related]
31. Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome.
Chan AW; Tong JH; Pan Y; Chan SL; Wong GL; Wong VW; Lai PB; To KF
Am J Surg Pathol; 2015 Mar; 39(3):304-12. PubMed ID: 25675010
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma.
Dai B; Ruan B; Wu J; Wang J; Shang R; Sun W; Li X; Dou K; Wang D; Li Y
Int J Clin Exp Pathol; 2014; 7(9):5645-54. PubMed ID: 25337205
[TBL] [Abstract][Full Text] [Related]
33. Risk factors of microvascular invasion, portal vein tumor thrombosis and poor post-resectional survival in HBV-related hepatocellular carcinoma.
Zhou L; Rui JA; Wang SB; Chen SG; Qu Q
Hepatogastroenterology; 2014 Sep; 61(134):1696-703. PubMed ID: 25436365
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
Stuart KE; Anand AJ; Jenkins RL
Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
[TBL] [Abstract][Full Text] [Related]
35. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
Kitai S; Kudo M; Izumi N; Kaneko S; Ku Y; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Kadoya M; Matsuyama Y; Matsunaga T
Dig Dis; 2014; 32(6):717-24. PubMed ID: 25376289
[TBL] [Abstract][Full Text] [Related]
36. Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma.
Wang JH; Wei W; Guo ZX; Shi M; Guo RP
J Transl Med; 2015 Feb; 13():41. PubMed ID: 25638165
[TBL] [Abstract][Full Text] [Related]
37. Cytohesin-2 as a novel prognostic marker for hepatocellular carcinoma.
Xu K; Gao J; Yang X; Yao Y; Liu Q
Oncol Rep; 2013 Jun; 29(6):2211-8. PubMed ID: 23545718
[TBL] [Abstract][Full Text] [Related]
38. Mastermind-like Transcriptional Coactivator 1 Overexpression Predicts Poor Prognosis in Human with Hepatocellular Carcinoma.
Wang J; Zhang SM; Wu JM; Lu ZC; Yang JR; Wu HS; Chen H; Lin B; Xu RH; Cao TS
Ann Clin Lab Sci; 2016 Sep; 46(5):502-7. PubMed ID: 27650617
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma].
Shi M; Zhang Y; Zhong C; Lin XJ; Zhang CQ; Li JQ
Ai Zheng; 2008 Jan; 27(1):83-7. PubMed ID: 18184471
[TBL] [Abstract][Full Text] [Related]
40. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
